Get the latest news, insights, and market updates on SOPH (SOPHiA GENETICS SA). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine. Nov 11, 2025 - $SOPH
SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine
Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made f Nov 11, 2025 - $SOPH
Complete Genomics and SOPHiA GENETICS Announce Integration of MSK-IMPACT® and MSK-ACCESS® Assays on DNBSEQ-T1+ Platform at AMP 2025
Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made f Nov 11, 2025 - $SOPH
SOPHiA GENETICS (SOPH): Revenue Growth Outlook Reinforces Bull Case Despite Persistent Losses and Premium Valuation
SOPHiA GENETICS (NasdaqGS:SOPH) remains unprofitable, with losses widening at an annual rate of 4% over the past five years. The company’s revenue is projected to climb 17.91% per year, outpacing the broader US market’s 10.5% growth rate. Despite robust revenue forecasts, investors are weighing the strong sales outlook against ongoing unprofitability and a premium Price-To-Sales Ratio compared to peers and the industry. See our full analysis for SOPHiA GENETICS. Next up, we'll see how these... Nov 5, 2025 - $SOPH
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10 Nov 3, 2025 - $SOPH
October 2025 Penny Stocks With Growth Potential
As of late October 2025, the U.S. stock market is experiencing mixed results, with Federal Reserve Chair Jerome Powell indicating uncertainty about a potential rate cut in December. In such a climate, investors might consider exploring penny stocks—companies that are often smaller or newer and can provide unique growth opportunities when supported by strong financials. These stocks may still hold relevance for those seeking to uncover promising investments beyond the well-known giants,... Oct 30, 2025 - $SOPH
AI in Biotechnology Market to Reach $11.4 Billion by 2030
“BCC Research analyzes how AI-driven discovery tools, predictive analytics, and scalable cloud platforms are transforming biotechnology's future.”Boston, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Artificial intelligence (AI) is transforming biotechnology, from accelerating drug discovery and streamlining clinical trials to enhancing diagnostics and genomic research. Valued at $3.8 billion in 2024, the global market for AI in biotechnology is projected to grow from $4.6 billion in 2025 to $11.4 billion b Oct 24, 2025 - $SOPH
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025
SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. Oct 21, 2025 - $SOPH
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple